HC Wainwright & Co. Maintains Buy on TriSalus Life Sciences, Raises Price Target to $12

Benzinga Newsdesk www.benzinga.com Positive 81.2%

Neg 0% Neu 0% Pos 81.2%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and raises the price target from $11 to $12.